Dr.Edward Maliski is an accomplished research scientist with three decades of experience in the development of pharmaceutical and biotechnology products across the drug development life cycle. Dr.Maliski is a executive leader and a strategist who contributed his expertise in project management and chemical research to facilitate the transfer of new discoveries into pharmaceutical products. He is motivating executive leader and mentor with extensive background in project management, business analysis, and software/database development. Effective team leader for reenergizing and refocusing existing groups or building new organizations. He has a excellent track record delivering consistent, solid progress while staying on time, in budget and without compromising quality. Experienced operating at local or enterprise level and across departments or continents, additionally, Dr.Maliski has worked with several successful start-up companies. | Dr. Ram Dhurjaty brings over 35 years of experience in the bio-medical and technology innovation in health-care, pharmaceutical and biotechnology industries. Throughout his career, he has built a strong reputation in industry and developed expertise in all aspects of new innovative devices for both research and commercialization. During his careers, spanning over three decades, Ram Dhurjaty has guided numerous Research & Development and commercialized projects such as Patient and Fetal Monitors, Medical Ultrasound, CT scanners, Digital and computed radiography. He is a recognized expert in low-noise Analog electronics for medical devices as well as Biophotonics, and was involved in development of appropriate medical systems for developing countries that are affordable and meet the unique needs of those countries. He is an expert on high density, high-wattage, power supplies and magnetics for medical and other applications; he has set goals to develop medical devices for both Research and commercialization in addition to analog systems and power supplies. He is also Member of Board of the Southeast YMCA in Rochester, He is a Private Pilot, mission pilot for the Civil Air Patrol, and is in Boards of management of various medical companies. |
Dr. Ravi Kiron has 25 years of experience in the pharmaceutical and healthcare industry,and currently Managing Director and Partner at Adjuvant Global Advisor LLC a leader in investor relations and venture M&A for Biotechnology,Pharmaceutical and Life Sciences technologies, prior to this is well versed in all aspects of drug discovery and delivery; pre-clinical and early clinical drug development; bioinformatics and database management; M&A, investment due-diligence, and alliance management. In a consulting practice for the last few years, he has provided business development and strategic advisory, regarding pipeline challenges and asset sales of discovery and development programs, IP and manufacturing plants, to clients in the pharma and biotech space, and Private Equity and Hedge Fund firms in the US/EU and Asia. Prior to Adjuvant, Dr. Kiron was the COO at LifeTech Innovations (LTI), a Business Development and Strategic Advisory consulting firm. As part of LTI, Dr. Kiron provided guidance to a number of biotech, private equity firms and hedge funds for strategy issues and capital raise needs. Dr. Kiron is also a cofounder of C2N Diagnostics, LLC that is in the CNS diagnostics arena. Before LTI, he was at Johnson & Johnson/ALZA Corporation, responsible for drug delivery technology & research strategy planning, in- and out-licensing, M&A and intellectual property management. Dr. Kiron spent 14 years at Pfizer Global R&D in the departments of Strategic Alliances, Project Management and Cardiovascular Drug Discovery. While at Pfizer, he was a primary architect of many US/non-US based partnerships, an acquisition/integration team member for Pfizer’s purchase of Warner-Lambert and Pharmacia Corporation, and other biotech’s. Dr. Kiron obtained experience in exploratory drug development as the project champion at Pfizer that led to the IND filing of Tarceva®, now used for treatment of multiple malignancies. He led drug discovery research teams in cardiovascular and metabolic disorders. Prior to Pfizer, Dr. Kiron was a biochemistry and medicine faculty member at Cornell University Medical Center in New York.
He holds a BSc in Chemistry and an MSc in Microbiology through colleges in Goa from Bombay University, India. He also earned a PhD in Biochemistry from the Indian Institute of Science in Bangalore, India and an MBA from Rensselaer in Hartford, Connecticut.
| Mr.Raj Laad brings more than 25 years in product and platform development, Raj Laad has been in the forefront of Technology, collaborating closely with the senior management, he has influenced and directed strategic vision of several clients, from startups to Fortune 500. As the CTO of Pristine InfoTech, Raj has spear-headed mobile workforce platform along with predictive and proactive business intelligence and analytics solutions. Earlier Raj was the President and CEO of GURU Technology, a consulting company. At GURU Technology, he was actively involved in all aspects of the business: from business development to client engagement, from product concept, definition to delivery, and managing mentoring distributed large teams to support. Having contributed to the development of early products and platforms at Lotus Development and Informix, Raj possess deep expertise in employee productivity improvement solutions. He has conceptualized and developed complex distributed real time SOA platforms for several industries such as health, retail, distribution, telecommunication, data communication, energy, security. Raj has deep knowledge of mobile, embedded and network management, and content management technologies. Raj holds a Masters Degree in Computer Science & Engineering from Indian Institute of Technology (IIT), Bombay. Raj has been actively involved in several social/professional activities, such as Board Member of “Partners in Ending Hunger”, Pratham, Vice President at “IIT-SINE (All-IIT Boston Chapter)” and is member of IEEE. |
